subject: Vision Shopsters: UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth [print this page] Introduction Introduction
The UK prescription pharmaceutical market was valued at $28.4 billion in 2009. Key growth drivers include growing use of chronic high-value innovative treatments driven by a rising elderly population, high public healthcare expenditure as proportion of total healthcare expenditure, relatively light pricing controls through the PPRS, and speedy domestic drug approvals.
Scope
*Overview of the UK's socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position
*Assesses the size of the UK's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
*Examines the UK's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
*Quantifies the UK's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.
Highlights
The UK pharmaceutical industry has to some extent been cushioned from the effects of the recession. However, the NHS now faces cuts and with price cuts to be implemented in Southern Europe further stimulating the parallel exportation of drugs out of these markets, branded drug sales in the UK market will certainly be impacted.
The UK's Department of Health is considering imposing mandatory generic substitution at the pharmacist level, as part of the renegotiated PPRS which came into effect in 2009. Mandatory substitution should boost generics volume uptake in the UK, but the extent of the increase is likely to be limited, given the widespread use of generics in the UK.
The UK has a strong track record for drug development. However, Roche and Novartis have threatened to pull out of the UK due to ongoing debates over drug pricing, expensive and bureaucratic clinical trials, and recent non-approval decisions by NICE. Also, a number of key players are downsizing their UK operations in an effort to reduce costs.
Reasons to Purchase
*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.
*Quantify the size and growth of the prescription pharmaceutical market in the UK, analyzing key therapy areas, brands and companies.
*Assess drivers and resistors of generic and biosimilars uptake in the UK as well as the level of erosion brands can expect to face post patent expiry.
Table Of Contents :
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
Country specific reports: 2
Global issue reports: 2
1. Executive Summary 3
Strategic scoping and focus 3
Key findings - UK healthcare drivers and resistors 4
Socio-demographic and economic analysis 8
UK socio-demographic trends 8
UK socio-economic trends 8
Healthcare system and drug regulatory analysis 10
UK healthcare expenditure 10
UK healthcare system overview 11
UK regulatory issues 11
UK pricing and reimbursement issues 11
Prescription pharmaceutical sales analysis 13
UK pharmaceutical market size 13
UK leading therapy areas 13
UK leading prescription pharmaceutical brands 13
UK pharmaceutical companies 13
Drug expiry analysis 15
UK generics market 15
UK brand erosion post patent expiry 15
UK biosimilars market 15
Pharmaceutical industry infrastructure analysis 17
UK pharmaceutical industry infrastructure overview 17
UK R&D infrastructure trends 17
UK manufacturing infrastructure trends 18
Related reports 20
Upcoming related reports 20
Table of Contents 21
2. Socio-demographic and economic analysis 22
To know more about this report & to buy a copy please visit :
